Sử dụng liệu pháp glucosamine trong viêm khớp thoái hóa

American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:1905–1915. Pendleton A, Arden N, Dougados M, et al.: EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000, 59:936–944. Kelly GS: The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Alt Med Rev 1998, 3:27–39. van der Kraan PM, de Vries BJ, Vitters EL, et al.: Inhibition of glycosaminoglycan synthesis in anatomically intact rat patellar cartilage by paracetamol-induced serum sulfate depletion. Biochem Pharmacol 1988, 37:3683–3690. van der Kraan PM, Vitters EL, de Vries BJ, van der Berg WB: High susceptibility of human articular cartilage glycosaminoglycan synthesis to changes in inorganic sulfate availability. J Orthop Res 1990, 8:565–571. Setnikar I, Giachetti C, Zanolo G: Pharmacokinetics of glucosamine in the dog and in the man. Arzneimittelforschun 1863, 36:729–733. Setnikar I, Palumbo R, Canali S, Zanolo G: Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993, 43:1109–1113. Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulphate: a review. Arzneimittelforschung 2001, 51:699–725. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND: The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Disp 2002, 23:217–225. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F: High performance liquid chromatographic determination of glucosamine in rat plasma. J Pharm Pharm Sci 2002, 5:176–180. Barclay TS, Tsourounis C, McCart GM: Glucosamine. Ann Pharmacother 1998, 32:602–603. Largo R, Alvarez-Soria MA, Diez-Ortego I, et al.: Glucosamine inhibits IL-1beta-induced NF-kappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:290–298. Glucosamine inhibits the synthesis of proinflammatory mediators in human osteoarthritic chondrocytes. Bassleer C, Rovati L, Franchimont P: Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998, 6:427–434. Setnikar I, Cereda R, Pacini MA, Revel L: Antireactive properties of glucosamine sulfate. Arzneimittelforschung 1991, 41:157–161. Setnikar I, Pacini MA, Revel L: Anti-arthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991, 41:542–545. Sandy JD, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998, 335:59–66. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M: N-acetylglucosamine prevents in IL-beta-mediated activation of human chondrocytes. J Immunol 2001, 166:5155–5160. Oegema TR, Deloria LB, Sandy JD, Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002, 46:2495–2503. Noyszewski EA, Wroblewski K, Dodge GR, et al.: Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum 2001, 44:1089–1095. Mroz PJ, Silbert JE: Effects of [3H]glucosamine concentration on [3H]chondroitin sulfate formation by cultured chondrocytes. Biochem J 2003, in press. Lippiello L: Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003, 11:335–342. These observations suggest that, by enhancing the “protective” metabolic response of chondrocytes to stress, glucosamine and chodroitin sulfate may improve its ability for repair and regeneration. Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003, 11:424–432. Glucosamine may have a beneficial effect in the prevention of articular cartilage loss in some patients with OA. Tiku ML: Role of lipid oxidative stress in osteoarthritis: glucosamine inhibits advanced lipoxidation reaction and scavenges reactive carbonyl intermediates [abstract]. Ann Rheum Dis 2003, 62(suppl):S376. Towheed TE, Anastassiades TP, Shea B, et al.: Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001, 1:CD002946. Houpt JB, McMillan R, Wein C, Paget-Dellio SD: Effect of glucosamine hydrochloride in the treatment of pain osteoarthritis of the knee. J Rheumatol 1999, 26:2294–2297. Chard JA, Tallon D, Dieppe PA: Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 2000, 59:414–418. McAlindon TE, LaValley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and metaanalysis. JAMA 2000, 283:1469–1475. Richy F, Bruyere O, Ethgen O, et al.: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003, 163:1514–1522. This data-analysis suggests efficacy for glucosamine on joint space narrowing and Western Ontario and McMaster Universities Osteoarthritis Index. Reginster JY, Deroisy R, Rovati LC, et al.: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001, 357:251–256. Pavelka K, Gatterova J, Olejarova M, et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113–2123. Mazzuca SA, Brandt KD, Lane KA, Katz BP: Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002, 46:1223–1227. Hughes R, Carr A: A randomized, double-blind, placebocontrolled trial of glucosamine sulfate as an analgesic in osteoarthritis of the knee. Rheumatology 2002, 241:279–284. This pragmatic study does not show symptomatic effect of glucosamine sulfate. Rindone JP, Hiller D, Collacott E, et al.: Randomized controlled trial of glucosamine for treating osteoarthritis of the knee. Wes J Med 2000, 172:91–94. Cohen M, Wolfe R, Mai T, Lewis D: A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003, 30:523–528. Tapadinhas MJ, Rivera IC, Bignamini AA: Oral glucosamine sulfate in the management of arthrosis: report on a multicenter open investigation in Portugal. Pharmatherapeutica 1982, 3:157–168. Towheed TE: Current status of glucosamine therapy in osteoarthritis. Arthritis Rheum 2003, 49:601–604. de Mattei M, Pellati A, Pasello M, et al.: High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cartilage 2002, 10:816–825. National Institutes of Health web site. Accessible at http://www.nih.gov. Reginster JY, Bruyere O, Henrotin Y: New perspectives in the management of osteoarthritis structure modification: facts or fantasy? J Rheumatol 2003, 30(suppl):14–20. Russell AS, Aghazadeh-Habashi A, Jamali F: Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002, 29:2407–2409.